Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 45

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 45
---
 beginning on the date of this prospectus
and through 30 days after the date of this prospectus, we have agreed that we will not, without the prior written consent of the Representatives,
(i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Series B Preferred
Stock or any other shares of our preferred stock ranking on parity with or senior to the Series B Preferred Stock or any securities
convertible into or exercisable or exchangeable into shares thereof or file any registration statement under the Securities Act with respect
to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part,
directly or indirectly, the economic consequence of ownership of the Series B Preferred Stock (iii) establish or increase a
put equivalent position or liquidate or decrease a call equivalent position in the Series B Preferred Stock within the meaning of
Section 16 of the Exchange Act, or (iv) confidentially submit or publicly file with the SEC a registration statement under the
Securities Act relating to the Series B Preferred Stock, or publicly disclose the intention to take any such action without the prior
written consent of the Representatives provided, however, that the foregoing shall not apply to the sale of the Series B Preferred
Stock to the Underwriters or the issuance of Series B Preferred OP Units by the Operating Partnership to us in connection with the
contribution of the net proceeds received in connection with the offering and sale of the Series B Preferred Stock.

Extended Settlement

We expect that delivery of the Series B Preferred
Stock will be made against payment thereof on or about November 20, 2025 which will be the fifth business day following the date of this
prospectus supplement (such settlement cycle being herein referred to as “T+ 5”). Pursuant to Rule 15c6-1 under
the Exchange Act, trades in the secondary market generally are required to settle in one business day unless the parties to any such trade
expressly agree otherwise. Accordingly, purchasers who wish to trade shares of Series B Preferred Stock prior to their delivery will
be required, by virtue of the fact that the shares of Series B Preferred Stock initially settle in T+5, to specify an alternate settlement
arrangement at the time of any such trade to prevent a failed settlement. Purchasers of